Triangle Park, NC). Where appropriate, animals injected i.p. or i.v. with CP were boosted i.p. with 1.4 mg of CP or with 1 × 107to 2 × 107 heat-killed Pasteur type Bacille Calmette-Gu6rin (BCG) 3 d before harvesting the macrophages. Macrophages were also taken 3-4 wk after mice were in~ected either i.p. or i.v. with 2 X 107 viable BCG. Boosted animals were injected i.p. with 2 × 10 autoclaved BCG 3 d before harvest.
Macrophage Cultivation. Primary cultures were established from peritoneal exudates as described by Cohn and Benson (8) . Approximately 6 × l0 s resident peritoneal cells or 10 × 106 cells from treated mice were suspended in 1 ml of minimum essential alpha medium (a-MEM, Gibco, Grand Island Biological Co., Grand Island, NY) containing 10% fetal calf serum (FCS) and added to 35-mm diam plastic culture dishes. After 2 h at 37°C in 5% CO2/95% air, the cultures were washed three times in calcium-and magnesium-free phosphate-buffered saline (PD) to remove nonadherent cells and incubated overnight in fresh ct-MEM plus 10% FCS or a-MEM plus 10% FCS and lymphokine. Fresh media were added daily.
Lymphokine-activated Macrophages. BCG-stimulated spleen cell supernates were prepared as described (9) and stored at -70°C after sterilization by filtration. Control supernatants were obtained from cultures of spleen cells from normal mice incubated with autoclaved BCG or alone. 20:4 Oxygenated Metabolites. Macrophage cultures maintained in 0t-MEM and 10% FCS were labeled for 16 h with 0.5 #Ci of [5, 6, 8, 9, 11, 12, 14, 15 -aH]20:4 ([aH]20:4, 62.2 Ci/mmol, sp act; New England Nuclear, Boston, MA). At the end of the labeling period, the cultures were washed three times with PD, overlaid with a-MEM (no serum), and the phagocytic stimulus added to initiate 20:4 release and metabolism. Media were removed after incubation for the appropriate periods under 5% CO2/95% air at 37°C. Cell monolayers were scraped into 1 ml of 0.05% Triton X-100 (Rohm and Haas, Co., Philadelphia, PA), and protein was determined by the method of Lowry et al. (10) , with bovine serum albumin as the standard. Aliquots of media and Triton X-100 cell lysates were removed for radioactivity determinations. 20:4 oxygenated products were extracted from culture media following a modification of the procedure described by Unger et al. (11) . In brief, 1 vol of absolute ethanol was added. After acidification with formic acid (85% wt/wt; 10 gl/ml of medium, final pH ~3), media were extracted twice with 1 vol each of chloroform. The chloroform phases were combined and taken to dryness under a stream of nitrogen. This procedure was repeated twice before the 20:4 metabolites were dissolved in 0.5 ml of the appropriate starting buffer for silicie acid chromatography or reverse-phase high performance liquid chromatography (HPLC).
Synthesis of
Prostaglandins were separated from lipoxygenase products and unreacted 20:4 by chromatography of concentrated chloroform extracts on 0.3-g columns of silicic acid (Unisil; 100-200 mesh, Clarkson Chemical Co., Williamsport, PA). Hydroxy-eicosatetraenoic acids (HETE) and unreacted 20:4 were eluted with 15 ml of chloroform. Subsequently, prostaglandins were recovered by etution with 10 ml of 5.0% methanol in chloroform. The solvent fractions were routinely collected into scintillation vials. After removal of solvents under a stream of air, radioactivity was measured by liquid scintillation counting in Hydrofluor (National Diagnostics Inc., Advanced Applications Institute, Inc., Sommerville, NJ).
For estimates of the total 20:4 oxygenated metabolites formed by macrophages, concentrated media extracts were subjected to HPLC. Columns (4.6-ram × 25-cm) of uhrasphere C-18 (Altex Scientific Inc., Subsid. of Beckman Instruments, Inc., Berkeley, CA) were eluted isocratically with 80 ml of solvent 1 (methanol/water/acetic acid, 75/25/0.01, vol/vol/vol) followed by 40 ml of solvent 2 (methanol/acetic acid, 100/0.01, vol/vol) at a flow rate of 1 ml/min. For the identification of prostaglandins, fractions 4-10 were pooled and evaporated under nitrogen. The residues were redissolved in 0.5 ml of solvent 3 (water/acetonitrile/benzene/aeetic acid, 76.7/23.0/0.2/0.1, vol/vol/vol/vol) and subjected to HPLC on ultrasphere C-18 columns eluted isocratically at a flow rate of 1 ml/min with solvent 3 (12) .
Quantitation of 20:4 Metabolites.
The molar quantities of 20:4 and 20:4 metabolites released by [SH]20:4-1abeled resident macrophages challenged with a phagocytic stimulus can be accurately calculated from their radiolabel content, provided the specific activity of 20:4 in cell phospholipids is accurately known (1) . The latter value is readily obtained from the phospholipid content (172 pmol/#g of cell protein) (13) and the 20:4 content (25 tool percent of phospholipid fatty acids) (1), together with the quantity of incorporated 20:4. Independent on February 23, 2013 jem.rupress.org
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ACTIVATED MACROPttAGE ARACItlDONIC ACID METABOLISM criteria, including fatty acid analysis, radioimmunoassay, and amino acid analysis, indicated radiolabel measurements provide an accurate (80% agreement) estimate of 20:4 release, PGEz synthesis, and LTC production, respectively (1, 2) . The radiolabel content of 20:4 metabolites recovered from silicic acid columns or HPLC was converted to pmol 20:4 metabolite//~g cell protein by the following formula ( where dpm~ is the radiolabel content of the 20:4 metabolite, dpm2 is the total radioactivity incorporated by cells, and 122.85 is a constant that includes the specific activity of 20:4 in cell phospholipid. Values for 20:4 metabolites were corrected for overall recoveries obtained alter extraction and chromatography, as described previously (14) . Total 20:4 release was the total quantity of radiolabel released by cells after a phagocytic stimulus. Molar quantities were calculated from the above formula using the total radiolabel in the medium as dpml.
Radiolabeled 20:4 Metabolite Standards. HPLC of all-labeled standards was used to identify macrophage-derived 20:4 metabolites. [5, 6, 8, 11, 12, 14, 15 -aH]PGE2, [5, 8, 9, 11, 12, 14, 15 -aH]6-keto PGF~,, [5, 6, 8, 9, 11, 12, 14, 15 -aH]PGF2~, and [5,6,8,9,11,12,14,15-aH] thromboxane B2 (TXB2) were purchased from New England Nuclear. all-labeled 5-HETE, 12-HETE, and 15-HETE were generated by published procedures using [aH]20:4 as the substrate. 5-HETE was isolated from human neutrophils exposed to calcium ionophore A 23187 (15), 12-HETE from human platelets similarly stimulated (16) , and 15-HETE after incubation of [aH]20:4 with soybean lipoxygenase (17) . 12-HETE and 15-HETE were extracted as described above. 5-HETE was extracted by the procedure described by Borgeat and Samuelsson (15) . All three HETE were purified by HPLC in solvent 1. The elution times were 45-57, 38-39, and 34-35 min for 5-HETE, 12-HETE, and 15-HETE, respectively.
Fatty Acid Analysis. Macrophage monolayers were rinsed into isotonic saline, and the lipids were extracted as described (1) . Fatty acid methyl esters were prepared by transesterification in methanolic HCI (13) . The methyl esters were then analyzed by gas-liquid chromatography on 1/8-in X 10-ft columns of 10% SP-2330 on Chromosorb WA/W (Supelco, Inc., Bellefonte, PA) at 180 ° with a carrier gas-flow rate of 30 ml/min. Phagocytic Stimuli. Zymosan was purchased from ICN K and K Laboratories, Inc., Plainview, NY, Stock solutions of zymosan were prepared in an a-MEM (18) . Formalin-treated CP (Coparvax, Burroughs Wellcome Co.) was centrifuged at 3,000 g for 20 rain and suspended at a final concentration of 7 mg/ml. Stock solutions (7 mg/ml) of lyophilized BCG were prepared in a-MEM plus 0.05% Tween 80 and sonicated.
Results
In Vivo Stimulation of Macrophages: Nonspecific Inflammatory Agents. Macrophages elicited with either PP or HIB released comparable amounts (100-110%) of 20:4 and its oxygenated products as did resident cells. However, THIO cells yielded greatly reduced amounts of 20:4 metabolites (10% of resident cells), as noted by others (19) . This effect could be reproduced by exposing resident macrophages in vitro to THIO (5 mg/ml) for 16 h with a >50% inhibition of 20:4 metabolism. Other eliciting agents used in this study (PP or HIB) were without effect on macrophage 20:4 metabolism. FiG. 1. 20:4 release and prostaglandin synthesis by resident and in vivo activated BCG, CP macrophages challenged with a maximum challenge of 160 #g unopsonized zymosan. Cells were purified by adherence, labeled with [~H]20:4 for 16 h in a-MEM plus 10% FCS, and exposed to zymosan for 90 min in a-MEM. 20:4 release was determined from the radiolabel content of medium, and prostaglandin synthesis was determined from the radiolabel content of silicic acid column eluates (5% methanol in chloroform). Injection procedures were those described in Materials and Methods, except for the two right panels in which nonimmune animals were injected 3 d before harvest of the peritoneal cells. 20:4 release is represented by the total height of each bar, and prostaglandin synthesis is represented as the height of the shaded area.
In vivo Activation of Macrophages: Agents Evoking
specific pathogen-free mice exhibited the greatest inhibition of 20:4 metabolism to bacterial vaccines. As we noted previously (1), resident macrophages converted >80% of the released 20:4 to oxygenated products, one-half of which were prostaglandins ( Fig. 1 ). IP CP macrophages, in addition to diminished 20:4 release, converted a smaller percentage (25%) of the released 20:4 to prostaglandins than did resident cells. Fig. 1 further illustrates that the route by which animals are immunized is an important determinant of macrophage 20:4 metabolism. 20:4 release and prostaglandin production by i.v. CP macrophages, in contrast to i.p. CP cells, was comparable to those of resident macrophages or somewhat elevated (100-130%, n = 3). Intraperitoneal boosting of animals previously injected with CP (i.v. or i.p.) effectively reduced peritoneal macrophage 20:4 metabolism to the same low level, wh!ch was 30% of i.p. CP cultures. The effect of the boost was more striking on i.v. CP than on i.p. CP cells because of the higher capacity of the former cultures to form 20:4 oxgenated products when challenged with zymosan. Immunologic specificity was not required because both i.p. BCG and i.p. CP boosts were equally effective ( Fig. 1 ). Macrophages harvested from nonimmune mice injected i.p. with the boosting dose of CP or BCG 3 d before harvest displayed less severe reductions in 20:4 metabolism. It appeared that both sensitization of the host with the vaccine as well as a local inflammatory response, perhaps a phagocytic event, were required for maximum reduction of 20:4 metabolism.
Kinetics of 20:4 Release and Prostaglandin Synthesis. Time-course experiments sup-
ported the observation (Fig. 1 ) that i.p. CP cells were less effective in producing 20:4 metabolites. Although the kinetics of 20:4 release and prostaglandin synthesis by i.p. CP and resident macrophages were similar in that both were linear for 60-90 rain, on February 23, 2013 jem.rupress.org
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the initial rates of release by i.p. CP cells were reduced ( Fig. 2) , which accounted for the diminished production of 20:4 metabolites. Nevei'theless, the experiment in Fig.  3 demonstrated that i.p. CP macrophages retained the capacity to respond to multiple exposures of zymosan by initiating new rounds of 20:4 release and prostaglandin synthesis, as shown previously for resident macrophages (1) . Both macrophage populations remained responsive provided maximum levels of ingestion were not reached. However, for each dose of zymosan, the response of i.p. CP cells was quantitatively less than that of resident cell controls. Table I indicated that, although differences in phospholipid fatty acid composition were evident between resident and i.p. CP cells, the 20:4 contents were similar and would not account for the differences in 20:4 metabolite production.
20:4 Metabolites Synthesized by i.p. CP Macrophages. Fig. 5 compares HPLC profiles of 20:4 metabolites synthesized by i.p. CP and resident cells under conditions that allow mutual separation of prostaglandins and lipoxygenase products. The profiles of resident cell products were dominated by a large peak of radiolabel in the runoff , the cultures were exposed to 60 p,g of zymosan at t = 0 in a-MEM (no serum). Media were removed from duplicate cultures at the indicated times and processed as described in Fig. 2 . An additional 100/lg of zymosan was added to the remaining cultures at 90 min (arrow). The media were harvested at subsequent times and processed. Values are the means ztz range. Similar results were obtained in two separate experiments.
volume of the column that consists of prostaglandins (80%) together with smaller amounts (20%) of unidentified polar 20:4 metabolites. Also evident are mono-HETE (fractions (25-40) and components with elution characteristics (15) of di-and tri-HETE. Contrasting this situation, a major percentage (70%) of the 20:4 released by i.p. CP cells was recovered as unreacted fatty acid. As a result, prostaglandin and HETE production were reduced proportionally. This finding indicates that the small percentage of 20:4 converted by i.p. CP macrophages to prostaglandins ( Fig. 1 ) occurs because of a lack of metabolism rather than shunting of the fatty acid into the lipoxygenase pathway. We next examined the cyclo-oxygenase products formed by resident and i.p. CP macrophages. Resident cells synthesized 6-ketoPGFl~ and PGE2 in the ratio of 1:1.5 (Fig. 6 ). PGE2 was also the major prostaglandin produced by i.p. CP populations, but the relative levels of 6-ketoPGF~ were reduced, and substantial amounts of a product with elution characteristics of TXB2 were recovered .The proportions of cyclo-oxygen- At the end of this period, the cultures were washed, overlaid with a-MEM, and exposed to 160 #g of zymosan. Media were removed from duplicate cultures and processed as described in Fig. 2 . Values are the means :t: range. O, resident cells; 0, i.p, CP cells.
ase metabolites of these CP-elicited cells was 1:4.1:16.8 for 6-ketoPGFa~, TXB2, and PGE2. These qualitative and quantitative differences in prostaglandins formed by the two macrophage populations were evident in three separate experiments.
In related experiments, the synthesis of leukotriene C by macrophages from specific pathogen-free mice immunized i.p. with CP was 2-3% of resident cell controls (C. A, Rouzer, personal communication).
Other Phagocytic Stimuli. We explored the question of whether 20:4 metabolism promoted by a zymosan challenge was representative of the macrophage response to phagocytic stimuli. For this purpose, 20:4 metabolism of cultured macrophages was compared after an in vitro challenge with zymosan, BCG, or CP. The kinetics of 20:4 release and prostaglandin synthesis were similar to those shown in Fig. 4 , regardless of the stimulus. Likewise, the same cyclo-oxygenase and lipoxygenase products were recovered. With resident cells, BCG promoted higher levels of 20:4 metabolism than did zymosan or CP at maximum stimulatory concentrations. However, BCG and CP at these levels (1 mg/ml and 1.2 mg/ml, respectively) led to cell loss that was not evident with zymosan. Diminished prostaglandin synthesis by i.p. CP macrophages on February 23, 2013 jem.rupress.org Cultures purified by adherence were incubated overnight in ~-MEM plus 10% FCS. The media were removed, and lipids were extracted from cells scraped into isotonic saline. Fatty acid analyses of isolated phospholipids were determined by gas-liquid chromatography after transesterifieation. occured with all three phagocytic stimuli, and BCG and CP were clearly less effective than zymosan.
In Vitro Exposure of Resident Macrophages to Lymphokines. Exposure to a 1-8 dilution of BCG lymphokine for 72 h was sufficient to morphologically activate resident macrophages. However, 20:4 release and prostaglandin (6-ketoPGFl~ and PGE2) synthesis by such cells was not significantly different from those of controls (no lymphokine) or cultures exposed to control supernatants. Dose-response experiments in which BCG lymphokines were varied from 2 to 25% in the culture medium also failed to either enhance or diminish zymosan-mediated 20:4 metabolism. A similar lack of effect was noted when 20:4 metabolism was monitored at 24-h intervals during 4-d cultivation of resident cells in a 1-8 dilution of BCG lymphokine. Modification of in vivo activated cells to release 20:4 products therefore reflects factors in addition to lymphokine-derived products.
Discussion
We previously concluded that resident peritoneal macrophages are a major source of 20:4 metabolites. In this report, we examined the capacity of populations of in vivo on February 23, 2013 jem.rupress.org Downloaded from stimulated inflammatory macrophages to convert 20:4 to cyclo-oxygenase and lipoxygenase products. We questioned whether a relationship exists between macrophage activation and the level of 20:4 production in response to an in vitro phagocytic stimulus. As shown in Fig. 7, there is a correlation (r = 0.91) Thus, the greater the degree of inhibition of toxoplasma replication, the greater the degree of macrophage activation. These values were taken from an overlapping study (9) in which common reagents were used to elicit cells for measurements of 20:4 oxygenated products and antitoxoplasma activity, thus providing valid comparisons for the two macrophage functions. Data are provided for the eleven macrophage populations in which both antitoxoplasma activity and PGE2 synthesis resulting from a maximum zymosan stimulus were measured. Values for PGE2 release are given in the text, except for BiG-activated cells. Methods for the determination of PGE2 synthesis by these macrophage populations are given in Materials and Methods or in the legend to Fig. 1 . In calculating the correlation coefficient between reduced antitoxoplasma activity and enhanced capacity for prostaglandin synthesis, data for THIO macrophages were omitted.
ACTIVATED MACROPtlAGE ARACHIDONIC ACID METABOLISM
to inflammatory stimuli in the absence of humoral factors by producing large quantities of 20:t oxygenated products (Table II) that can have immediate consequences on the vasculature (23) and on the immune system (24) . The considerable synthetic capacity of the macrophage is compared in Table Ii with that of guinea pig neutrophils for which similar quantitative data are available. Activated macrophages, as shown in this study for i.p. CP cells, responded to in vitro inflammatory stimuli by a burst of 20:4 release and the subsequent synthesis of cyclo-oxygenase and lipoxygenase products. Although their phagocytic capacity appears unimpaired (W. A. Scott, unpublished results), 20:4 metabolism was reduced. Down regulation was evident at the level of the inducible phospholipase. In addition, there is a failure to quantitatively metabolize released 20:4 together with specific inactivation (or inhibition) of the prostacyclin synthetase, as noted earlier (19) , and of enzyme(s) for leukotriene C synthesis. The implication of these findings is that activated macrophages within chronic inflammatory foci release a mixture of 20:4 metabolites distinct from resident cells (Table II) . The elimination of the vasoactive agents prostacyclin and leukotriene C, coupled with an overall reduction in synthetic capacity, might be a factor in limiting the immune response. Activated macrophages, however, might continue to be a considerable source of 20:4 metabolites when compared to other cell types (Table II) .
The factors that regulate macrophage 20:4 metabolism remain to be elucidated. Our results suggest from a comparison of i.p. CP and i.v. CP cells that a reduced synthetic capacity is a localized response to bacterial antigens. The lessened production (25) . This point of view is supported by the finding that both bacteria are potent triggers of macrophage 20:4 metabolism. Clearly, additional factors are involved in regulating macrophage 20:4 metabolism, as shown by the priming effect of a systemic (i.v.) immunization when followed by an i.p. boost. 20:4 metabolism by the resulting macrophage population was decreased significantly below that of cells from nonimmune animals given the same boosting injection. In vitro activation of macrophages with spleen cell products indicated that factors in addition to lymphokines are required to regulate the release of 20:4 products.
It is now appropriate to examine the relative contributions of several variables, such as the rates of antigen clearance and deposition, the influx of mononuclear phagocytes into the inflammatory site, and the role of the host immune system, in controlling the synthesis of inflammatory lipids by macrophages.
Summary
Levels of zymosan-induced arachidonic acid (20:4) metabolism by peritoneal macrophages elicited with inflammatory agents and resident macrophages were similar. Thyioglycollate (THIO)-elicited macrophages represented the exception; however, the diminished metabolism by these cells was reproduced by exposing resident cells to 5 mg/ml THIO broth in vitro. In contrast, reduced prostaglandin synthesis by macrophages from mice variously treated with the immunologic agents, Cornbacterium parvum or Bacille Calmette Gu~rin (BCG), closely correlated with enhanced antitoxoplasma activity, one measure of macrophage activation. This relationship, although not causative, suggested that the capacity for 20:4 metabolism is a function of the macrophage activation state. Modulation of macrophage 20:4 metabolism in vivo apparently required factors in addition to lymphocyte-derived products. Treatment of resident macrophages in vitro with BCG lymphokine was without effect on 20:4 release or prostaglandin synthesis. Activated macrophages from animals inoculated i.p. with C. parvum exhibited reduced 20:4 release and also failed to metabolize 70% of the 20:4 released in response to a zymosan stimulus. Consequently, the quantities of 20:4 metabolites formed were significantly less than expected from 20:4 release. These activated macrophages displayed greatly reduced synthesis of prostacylcin and leukotriene C compared with other 20:4 metabolites. It appeared that factors that regulate macrophage 20:4 metabolism influence the level of the inducible phospholipase and synthetic enzymes for specific 20:4 oxygenated products.
